FDA refuses to approve AstraZeneca’s sBLA for Fasenra in CRSwNP

The US Food and Drug Administration (FDA) has refused to approve the supplemental biologics license application (sBLA) of AstraZeneca’s asthma drug Fasenra (benralizumab) for the ... Read More